*3.2. Super-SLH Preparation and Characterization*

2.8% *w/w* with small standard deviation.

FS

Captex 300

*3.2. Super-SLH Preparation and Characterization*  FEN-loaded SLH were fabricated with varying (i) lipid types, (ii) silica types, and (iii) drug loads. The compositions and drug loads of the fabricated formulations are summarized in Table 1. Subsequently, fabricated SLH formulations were identified and categorized according to type of lipid used to dissolve FEN (PG8 or C300), type of silica microparticles used to stabilize precursor liquid lipid (FS or MPS), and drug load based on % Seq ranging from 80% Seq (unsaturated) to 600% Seq (highly supersaturated). Furthermore, liquid lipid formulations were prepared at 80% Seq in both lipids, in order to compare the influence of solidification on drug release and solubilization. Drug loads ranging from 3.8 to 22.7% *w/w* were attained for PG8-containing formulations and 3 to 18.8 % *w/w* for C300-containing formulations. Furthermore, three formulations were randomly selected to evaluate the homogeneity of FEN throughout the formulation and to assess the drug loading efficiency (Table S1). All tested formulations displayed high drug loading efficiency of at least 94 ± FEN-loaded SLH were fabricated with varying (i) lipid types, (ii) silica types, and (iii) drug loads. The compositions and drug loads of the fabricated formulations are summarized in Table 1. Subsequently, fabricated SLH formulations were identified and categorized according to type of lipid used to dissolve FEN (PG8 or C300), type of silica microparticles used to stabilize precursor liquid lipid (FS or MPS), and drug load based on % Seq ranging from 80% Seq (unsaturated) to 600% Seq (highly supersaturated). Furthermore, liquid lipid formulations were prepared at 80% Seq in both lipids, in order to compare the influence of solidification on drug release and solubilization. Drug loads ranging from 3.8 to 22.7% *w*/*w* were attained for PG8-containing formulations and 3 to 18.8 % *w*/*w* for C300-containing formulations. Furthermore, three formulations were randomly selected to evaluate the homogeneity of FEN throughout the formulation and to assess the drug loading efficiency (Table S1). All tested formulations displayed high drug loading efficiency of at least 94 ± 2.8% *w*/*w* with small standard deviation.


**Table 1.** The calculated composition of the fabricated FEN-loaded liquid and silica-lipid hybrid (SLH) **Table 1.** The calculated composition of the fabricated FEN-loaded liquid and silica-lipid hybrid (SLH) formulations.


80% FS C300 80 3 48.5 48.5 200% FS C300 200 7.1 46.4 46.4 400% FS C300 400 13.4 43.3 43.3 600% FS C300 600 18.8 40.6 40.6


**Table 1.** *Cont.*

\* Liquid formulations do not contain any silica (solid carrier).
